Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|9|1|129-135

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.9, Iss.1, 2018-01, pp. : 129-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histological transformation from non‐small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 800-804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathological characteristics and outcomes of ROS1‐rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 413-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 228-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 159-163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 655-658

John Wiley & Sons Inc

Access to resources Recommend Favorite